Ann: Positive outcomes in first animal study involving Plexaris, page-8

EX1 have reported on an Early Stage Proof of Concept Trial, for which the main purpose was to test the manufacturing of Plexaris & Exomeres using LEAP technology.  There were no safety issues or adverse events. (Tick).  

Investing here initially, my main attraction to this company was that they would be commencing trials for Plexaris in wound healing in humans in 2019.  Some wounds are incredibly hard to heal, albeit it using the best technology in impregnated dressings & negative pressure vacuum assisted devices.  This technology is new & targeting wounds at cellular level.

What I found very positive in this ANN also:

”Wound tissue tensile strength showed positive signs of DOSE-RESPONSE with Plexaris treatment, being the explorative primary efficacy outcome of the study”.

To not bore people to death here, EX1 have to start somewhere & are now moving on to animal trials in larger animals, which are not long.  The rat studies were looking at healing of a wound incision over 1/52.

All of this is necessary prior to human studies & approval from Ethics Committee & TGA for Plexaris.  We have invested here in a something that is a very new clinical area, that may progress very quickly on good results.

Non healing wounds in people that have chronic health issues such as diabetes, peripheral vascular disease
& impaired immune dysfunction (elderly included), it would be far better to heal the wound than loss of limbs or worse.  Looking forward to progress this year & Happy that EX1 have delivered Early Proof of Concept Trial results a bit sooner that expected...very early February 2019.  GLTAH